ASCO 2023 | Indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an indirect comparison of momelotinib and fedratinib in patients with myelofibrosis (MF). The study incorporates data from three Phase III trials of momelotinib (SIMPLIFY-1, NCT0196983; SIMPLIFY-2, NCT02101268; MOMENTUM, NCT04173494) and two Phase III/II trials of fedratinib (JAKARTA, NCT01437787; JAKARTA2, NCT01523171). The comparison revealed that momelotinib treatment had superior safety outcomes, regardless of whether patients had received prior ruxolitinib treatment or not. Momelotinib demonstrated a lower incidence of adverse events, including anemia and thrombocytopenia, and gastrointestinal (GI) toxicity.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
